Sonoma Pharmace…
ProfileJobs

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Suggest Edit
    • Technologybig tech

    Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

    Revenue(FY, 2017)
    $12.8 M
    Market capitalization(2016-12-05)
    $20.9 M
    Type
    Public
    HQ
    Petaluma, US
    Size (employees)
    38 (est)+12%
    Website
    oculusis.com
    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US
    Report incorrect company information

    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations

    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma and Herten
    Petaluma, US (HQ)
    1129 N McDowell Blvd
    Herten, NL
    6049 LX Herten/Roermond
    Show all (2)
    Report incorrect company information

    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials and Metrics

    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials

    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $12.83 m in FY, 2017 which is a 15% decrease from the previous period.
    USD

    Revenue (Q2, 2018)

    		4.3 m

    Gross profit (Q2, 2018)

    		1.8 m

    Gross profit margin (Q2, 2018), %

    		42.7%

    Net income (Q2, 2018)

    		(2.9 m)

    EBIT (Q2, 2018)

    		(2.9 m)

    Market capitalization (5-Dec-2016)

    		20.9 m

    Closing share price (5-Dec-2016)

    		4.9

    Cash (30-Sep-2017)

    		10 m

    EV

    		10.9 m
    Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		13.7 m13.9 m15.1 m12.8 m

    Revenue growth, %

    		1%9%(15%)

    Cost of goods sold

    		5.3 m6.6 m7.9 m7.2 m

    Gross profit

    		8.4 m7.3 m7.2 m5.7 m
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Revenue

    		4.1 m3.3 m3.4 m3.3 m3.2 m3.7 m4.1 m3.8 m3.8 m4.1 m3.4 m3.8 m4.3 m

    Cost of goods sold

    		1.4 m1.2 m1.5 m1.5 m1.6 m1.8 m2 m2.3 m1.9 m2 m1.7 m2.1 m2.5 m

    Gross profit

    		2.7 m2.1 m1.9 m1.7 m1.7 m1.9 m2.1 m1.5 m1.9 m2.1 m1.7 m1.8 m1.8 m

    Gross profit Margin, %

    		66%64%56%53%51%51%52%40%50%51%51%46%43%
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		5.5 m6.1 m7.5 m17.5 m

    Accounts Receivable

    		1.8 m1.5 m2.3 m2.1 m

    Inventories

    		647 k592 k1.5 m2.2 m

    Current Assets

    		9.5 m9.6 m12.9 m22.6 m
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Cash

    		3.2 m3.4 m5 m3.5 m2.2 m8.8 m8 m6.1 m5 m3.3 m19 m12.6 m10 m

    Accounts Receivable

    		2.4 m2.6 m2 m2.1 m1.4 m2.5 m2.6 m2.7 m2.6 m2.3 m2 m2.7 m3 m

    Inventories

    		749 k970 k1.3 m1.2 m1.4 m1.5 m1.7 m1.6 m2 m2.1 m2.1 m2.4 m2.6 m

    Current Assets

    		6.9 m7.5 m8.7 m7.3 m5.2 m13.3 m12.7 m11.1 m10.5 m8.4 m25.1 m19.3 m17.2 m
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		3.7 m(8.2 m)(10.2 m)9.3 m

    Depreciation and Amortization

    		284 k253 k244 k248 k

    Inventories

    		(126 k)(627 k)(382 k)(675 k)

    Accounts Payable

    		848 k222 k429 k(58 k)
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    		(1.4 m)(611 k)(70 k)(718 k)(5.9 m)(2.3 m)(1.8 m)(3.1 m)(2.6 m)(1.9 m)16.2 m

    Accounts Payable

    		943 k1.1 m942 k1.2 m1.2 m1.5 m1.4 m1.3 m1.1 m
    show all
    USDY, 2017

    EV/EBIT

    		-3.8 x

    EV/CFO

    		-1.3 x

    Financial Leverage

    		1.2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Laird
    Technology - Subsidiary
    ACTIVE Network
    Technology - Subsidiary
    HTEC
    Technology - Public
    Vislink
    Technology - Public
    Compare competitors
    Download PDF